Allogene Therapeutics(ALLO)

SOUTH SAN FRANCISCO, CABiotechnology1 H-1B visas (FY2023)

Focus: Allogene Therapeutics is a public biotechnology company focused on developing allogeneic CAR-T cell therapies for hematologic malignancies, autoimmune diseases, and solid tumors. The company operates at mid-cap scale with 1,001–5,000 employees and is headquartered in South San Francisco.

Cell Therapy

Profile data last refreshed 11h ago · AI intelligence enriched 2mo ago

Funding Stage

PUBLIC

Employees

1001-5000

Open Jobs

18+33 this month

Hot — 48 jobs added in 30d

Net +33 (48 new, 15 removed). Aggressive expansion phase.

Should You Work at Allogene Therapeutics?

AI assessment

Allogene offers meaningful science and pipeline optionality but presents elevated financial and execution risk for career-focused professionals seeking stability.

Why Work Here

Leading position in allogeneic CAR-T, a differentiated modality with significant unmet-need potential in oncology and autoimmunity.
Diverse pipeline with 13 active programs spanning Phase 1–2, offering exposure to multiple indication areas (lymphoma, myeloma, renal cell carcinoma, lupus).

Data completeness

5/9 — Partial

Company HealthStrong

Pipeline

Early-stage

13 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$22K

Pipeline & Clinical Trials

allogeneic CAR T cell therapy

Hematologic Malignancies

N/A

Follow-Up for Study Participants Treated With an Allogeneic CAR T-Cell Product

Hematologic Malignancies

N/A

Clinical Trials (1)

Help build intelligence for Allogene Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Strong R&D investment culture: $192M R&D spend in FY 2025 demonstrates commitment to advancing next-generation cell therapy.

Watch Out For

Severe cash burn: $257.6M net loss in FY 2025 on only $22K revenue; $75M cash position creates near-term runway pressure.
No Phase 3 programs and minimal clinical traction; lead program (cemacabtagene ansegedleucel) remains in Phase 2 with no near-term approval catalysts.

Generated by Claude from Allogene Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

NCT06925685Follow-Up for Study Participants Treated With an Allogeneic CAR T-Cell Product

N/A

allogeneic CAR T cell therapy

Advanced/Metastatic Clear Cell Renal Cell Carcinoma

Phase 1

Clinical Trials (2)

NCT05714345Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy

Phase 2

NCT05000450Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

Phase 1/2

allogeneic CAR T cell therapy

Systemic Lupus Erythematosus

Phase 1

ALLO-501

Relapsed/Refractory Large B Cell Lymphoma

Phase 1

Clinical Trials (1)

NCT03939026Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma

Phase 1

allogeneic anti-BCMA CAR T cell therapy

Relapsed/Refractory Multiple Myeloma

Phase 1

ALLO-329

Systemic Lupus Erythematosus (With and Without Nephritis)

Phase 1

Clinical Trials (1)

NCT07085104A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease

Phase 1

ALLO-316

Advanced/Metastatic Clear Cell Renal Cell Carcinoma

Phase 1

Clinical Trials (1)

NCT04696731Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Phase 1

ALLO-715

Relapsed/Refractory Multiple Myeloma

Phase 1

Clinical Trials (1)

NCT04093596Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL)

Phase 1

allogeneic anti-BCMA CAR T cell therapy

Relapsed/Refractory Multiple Myeloma

Phase 1/2

ALLO-501A

Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma

Phase 1/2

Clinical Trials (1)

NCT04416984Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)

Phase 1/2

allogeneic anti-CD19 CAR T cell therapy

Relapsed/Refractory Large B Cell Lymphoma

Phase 1/2

cemacabtagene ansegedleucel

Large B-cell Lymphoma

Phase 2

Clinical Trials (1)

NCT06500273Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

Phase 2

Interview Prep Quick Facts

Portfolio: 9 clinical trials

Top TAs: Oncology, Immunology

H-1B (2023): 1 approval

Publications: 26 in PubMed

SEC Filings: 2 available

Open Roles: 18 active jobs

Therapeutic Area Focus

Oncology

8 pipeline

Immunology

1 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

$22K77%

R&D Spend

$192M(874086%)21%

Net Income

-$258M

Hiring Trend

Stable

Open Roles

Added

-3

Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Research Publications(10)

Recent peer-reviewed publications with author affiliations at this company

Allogeneic CD70-Targeted Chimeric Antigen Receptor T-Cell Therapy for Advanced Renal Cell Carcinoma: Results From the Phase I TRAVERSE Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

2026

PMID:42447427

DisTAL-Seq: A TALEN-specific adaptation of DISCOVER-Seq for off-target profiling.

Molecular therapy. Nucleic acids

2026

PMID:41883584

Showing 5 of 10 publications

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Allogene Therapeutics(ALLO)

Should You Work at Allogene Therapeutics?

Why Work Here

Pipeline & Clinical Trials

Watch Out For

Recent News · Allogene Therapeutics(10)

Open Jobs (18)

Senior Scientist, Computational Biology (Contractor)

Senior Associate Scientist, Analytical Science (Contract)

Coordinator, Corporate Affairs

Senior Manager of GxP Learning and Development

Senior Director, Quality Systems and Compliance

Patient Operations Management Associate (Contract)

Sr. Scientist, Gene Editing Materials Process Development(temp)

Sr. Assoc. Scientist, Process and Product Development (Contract)

Sr. Associate Scientist, Drug Substance-Data Science (Contract)

Manager, Pharmacovigilance Operations

Senior Paralegal

Senior Manager, External Manufacturing

Senior Engineer, Facilities

Senior Manager, CMC Project Management

Senior Associate Scientist, Analytical Development (Contract)

Senior Counsel, Corporate, Securities & Transactions

Vice President, Clinical Development (Oncology)

Medical Director, Clinical Development (Oncology)

Financials (FY2025)

Hiring Trend

Visa Sponsorship

Research Publications(10)